Children's Oncology Group

St. Baldrick's Foundation Funds $8.9 Million in Grants to Support the Most Promising Childhood Cancer Research

Retrieved on: 
수요일, 7월 27, 2022
Aurora, University, Research institute, The Center to Prevent Youth Violence, Twitter, Instagram, Foundation, Wipe Out Kids Cancer, CEO, Survivor, Research, Nationwide Children's Hospital, Hospital for Sick Children (Toronto), Massachusetts General Hospital, University of Minnesota School of Public Health, Multimedia, Volunteering, Anschutz Medical Campus, Cancer, Hospital, Johns Hopkins School of Medicine, Philosophy, Pediatrics, YouTube, University of Alabama, Adolescence, Children's Oncology Group, University of Minnesota School of Dentistry, University of California, San Diego, The Research Institute at Nationwide Children's Hospital, Public health, Child, Pharmaceutical industry, Medical imaging, Toy, Mass, Facebook, St. Baldrick's Foundation

This is why the St. Baldrick's Foundation funds the most promising research no matter where it takes place from your backyard institution to other cutting edge research facilities treating childhood cancers around the globe.

Key Points: 
  • This is why the St. Baldrick's Foundation funds the most promising research no matter where it takes place from your backyard institution to other cutting edge research facilities treating childhood cancers around the globe.
  • To donate to critical childhood cancer research or to learn the many ways you can get involved, visit StBaldricks.org.
  • Become an advocate and join the Speak Up for Kids' Cancer advocacy action network to encourage federal lawmakers to continue to fund childhood cancer research.
  • The St. Baldrick's Foundation, the largest charitable funder of childhood cancer research grants, is on a mission to give kids a lifetime by supporting the most promising research to find cures and better treatments for all childhood cancers.

Artax Biopharma Appoints D. Scott Batty, Jr., M.D. as Chief Medical Officer

Retrieved on: 
수요일, 6월 29, 2022
Tufts University School of Medicine, National, Health, View, Patient, Artax, Bureau of Oceans and International Environmental and Scientific Affairs, Medical Corps (United States Army), CEO, Liver transplantation, National Institute, MedStar Georgetown University Hospital, Walter Reed Army Medical Center, Therapure BioPharma Inc, Behavior, Immunosuppression, Medical Affairs Bureau, CTI, Company, Industry, TCR, Degenerative disease, NIH, CMO, Tcell, Immune system, National Institute of Diabetes and Digestive and Kidney Diseases, Risk, Lymphoma, Regulation, Kidney, NIDDK, University, Autoimmune disease, Digestive, Immunomodulation, Infection, Leadership, Lieutenant colonel, Children's Oncology Group, Bristol Myers Squibb, Multimedia, Organ, Transplant, Vaccine, Dentistry, NCK

CAMBRIDGE, Mass., June 29, 2022 /PRNewswire/ -- Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T Cell-mediated diseases, today announces the appointment of D. Scott Batty, Jr., M.D. as Chief Medical Officer. Dr. Batty will direct the Company's scientific and clinical research programs, including Artax's ongoing Phase 1 clinical trial evaluating AX-158, the Company's first-in-class, oral small molecule immunomodulating agent that selectively modulates inappropriate T cell activation, a known cause of autoimmune disease. Importantly, AX-158 has the potential to treat T Cell-mediated diseases without the risk of immunosuppression.

Key Points: 
  • Prior to joining Artax, Dr. Batty was VP of Regulatory and Scientific Affairs for CTI, Inc., a privately held contract research organization.
  • Previous roles included Chief Medical Officer at Medeor Therapeutics, which developed an organ transplantation cell therapy platform to avoid the use of pharmacologic immunosuppression; Chief Executive Officer of ImmunArray Ltd., and Vice President of Global Medical Affairs for Genzyme Transplant and Oncology Group.
  • Dr. Batty was also a Global Director of Medical Affairs for the belatacept immunosuppression program while at Bristol-Myers Squibb.
  • Artax Biopharma is a clinical-stage biotechnology company transforming TCell-mediated disease treatment by developing innovative small molecules that modulate the immune system.

Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting

Retrieved on: 
수요일, 6월 1, 2022
Transducin, MD Anderson Cancer Center, Adult, Large-cell lung carcinoma, Cell membrane, Research, Society, The James Cancer Hospital, Doctor of Philosophy, AACR, Toxicity, WNT, Plasma, Metastasis, CEO, ASCO, AML, Research institute, Toxic leukoencephalopathy, MTD, Plantar fibromatosis, Sarcoma, Therapy, Patient, Acute myeloid leukemia, Lymphoma, Cancer Prevention and Research Institute of Texas, CDT, Poster, Children's Oncology Group, Index (publishing), NSCLC, Safety, Cancer prevention, Pharmaceutical industry

HOUSTON , June 1, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that results from a Phase 1 study of tegavivint in patients with desmoid tumors will be featured in a poster presentation and discussion session at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO 2022). ASCO 2022 is being held June 3-7, 2022, in Chicago, Illinois.

Key Points: 
  • Increased expression of beta-catenin and TBL1 are associated with metastasis and poor prognosis in a broad range of tumor types.
  • The poster details results from the Phase 1 trial in adult patients with progressive, unresectable desmoid tumors.
  • The primary objectives of the study were to evaluate safety and to determine the maximum tolerated dose (MTD), the recommended Phase 2 dose (RP2D), and exploratory efficacy.
  • These cancer indications, like desmoid tumors, are associated with nuclear beta-catenin overexpression, which has historically been considered undruggable.

St. Jude research highlighted at annual meeting of the American Society of Clinical Oncology

Retrieved on: 
화요일, 5월 31, 2022
Department, Brain, The Ride to Conquer Cancer, Children's Oncology Group, Hospital, Social media, Developmental Neurobiology, Survival, Cancer, World, Patient, Pediatrics, Treatment, American Society of Clinical Oncology, Society, Survival rate, NCI-designated Cancer Center, Cell, Genetics, Research, Global health, National Cancer Institute, Aircraft pilot, CST, Child, List, Global Oncology, ASCO, Neuroblastoma, Life, Department of Oncology, University of Cambridge, Childhood cancer, St. Jude Children's Research Hospital, McCormick Place, Medicine, Medulloblastoma

MEMPHIS, Tenn., May 31, 2022 /PRNewswire/ -- Professionals from St. Jude Children's Research Hospital will share original research and expertise at the American Society of Clinical Oncology (ASCO) annual meeting. The meeting will be held June 4–8, at McCormick Place in Chicago and include online lectures.

Key Points: 
  • Learn best practices and hear insights from St. Jude Children's Research Hospital oncologists, psychologists, scientists and more at the annual gathering of clinical oncology experts.
  • MEMPHIS, Tenn., May 31, 2022 /PRNewswire/ -- Professionals from St. Jude Children's Research Hospital will share original research and expertise at the American Society of Clinical Oncology (ASCO) annual meeting.
  • ASCO is the premier professional society for clinical oncology, representing nearly 45,000 individuals dedicated to cancer care.
  • Amar Gajjar , M.D., Department of Pediatric Medicine and Department of Oncology chair, will receive the 2022 ASCO Pediatric Oncology Award .

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Present Expansive, Diverse and Compelling New Cancer Research at the 2022 ASCO Annual Meeting

Retrieved on: 
목요일, 5월 26, 2022
Bleomycin, Lymphoma, Physician, Cancer, Multiple myeloma, Education, Master of Science, RWJBarnabas Health, Children's Oncology Group, Daratumumab, Medicine, Annual general meeting, Social media, Population, Associate Director of National Intelligence and Chief Information Officer, Survival, CPI, Rutgers Biomedical and Health Sciences, 2021 Essex County Council election, Patient, Hodgkin lymphoma, Health, FACP, Associate, Lung cancer, Society, Oncology, Rutgers Cancer Institute of New Jersey, American Society of Clinical Oncology, Adult, CHL, Research, Pembrolizumab, DO, Brentuximab vedotin, Immunity, Leukemia, Safety, ASCO, Prognosis, Colorectal cancer, LL, ALL, Acute leukemia, Trial of the century, Outline of health sciences, SUMO protein, Pharmaceutical industry, Medical imaging

NEW BRUNSWICK, N.J., May 26, 2022 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present intriguing data from their innovative cancer clinical research program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held both in person in Chicago and online from June 3-7. A total of 14 presentations, including 13 abstracts and one education session, have been accepted, highlighting research advances in several types of cancer, including leukemia, lymphoma, lung cancer and colorectal cancer.

Key Points: 
  • NEW BRUNSWICK, N.J., May 26, 2022 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present intriguing data from their innovative cancer clinical research program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held both in person in Chicago and online from June 3-7.
  • A total of 14 presentations, including 13 abstracts and one education session, have been accepted, highlighting research advances in several types of cancer, including leukemia, lymphoma, lung cancer and colorectal cancer.
  • "The high-powered lineup of valuable data to be unveiled at this year's ASCO Annual Meeting reflects the command of medicine, technical expertise and leading-edge thinking that are the hallmarks of our cancer research program.
  • The full list of presentations at the 2022 ASCO Annual Meeting follows:

​​Dave Cantin Group Announces Formation of New Nonprofit, DCG Giving, to Benefit Cancer Research and Treatment

Retrieved on: 
목요일, 2월 24, 2022
Other Health, Finance, Other Automotive, Oncology, Professional Services, Philanthropy, Children, Fund Raising, Foundation, Family, Automotive, Science, Other Philanthropy, Consumer, Research, Health, Mergers and acquisitions, Partnership, Leukemia, City, DNT, Columbia University Irving Medical Center, Hospital, Community, American Cancer Society, Pediatrics, CFO, COVID-19, Industry, COG, Organization, Columbia University, DCG, Institute for Mergers, Acquisitions and Alliances, Child, Heart, Cox Automotive, Acquisition, Adult, Children's Oncology Group, Rockefeller Center, GM, Columbia, Organic, Hope, Teaching hospital, MD, Research, CEO, Foundation, Adolescence, Pharmaceutical industry, Birth control, Financial services, Cancer

According to the American Cancer Society, COVID-19 reduced its ability to fund cancer research by 50% in 2020 the lowest investment this century.

Key Points: 
  • According to the American Cancer Society, COVID-19 reduced its ability to fund cancer research by 50% in 2020 the lowest investment this century.
  • By establishing DCG Giving, DCG hopes to help close that gap and allow critical research and treatment to continue.
  • Dave Cantin, founder and CEO of Dave Cantin Group, was personally impacted by cancer when he was diagnosed with leukemia in 2011.
  • DCG Giving is a nonprofit that aims to benefit child and adolescent cancer research and treatment nationwide.

Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy

Retrieved on: 
화요일, 1월 4, 2022
CHOP, RNA transfection, University, Pediatrics, Children's Hospital, Association, Lists of World Heritage Sites, Childhood leukemia, Failure, Health, Doctor of Philosophy, Patient, Pathology, Immune system, Hospital, Exon, Oncology, Cancer, RNA, Children's Hospital of Philadelphia, Science Publishing Group, American Association for Cancer Research, CD19, Disease, Observation, Lymphatic system, B-ALL, American Association, Division, Biomarker, Inotuzumab ozogamicin, Antibody, Diagnosis, Population, Leukemia, Medical laboratory, Canadian Aviation Regulations, Children's Oncology Group, DOI, Immunotherapy, CAR, Associate, Program, ALL, Alternative splicing, Philadelphia, Vaccine, Child, MD, CD22

One way to achieve this is by paying close attention to aberrant RNA splicing events, like those described in our study."

Key Points: 
  • One way to achieve this is by paying close attention to aberrant RNA splicing events, like those described in our study."
  • Adoptive immunotherapy, in which a patient's own immune system is used to kill cancer cells, has been a breakthrough in the treatment of B-ALL.
  • Although earlier studies had shown that CD22 undergoes alternative splicing, the role of these CD22 isoforms in the context of immunotherapy had not been characterized.
  • In one case, it was the only CD22 isoform, and predictably that patient did not respond to treatment with inotuzumab.

St. Baldrick's Foundation Welcomes Smita Bhatia, M.D., M.P.H., from the University of Alabama at Birmingham to its Board of Directors

Retrieved on: 
금요일, 11월 12, 2021
MPH, Society, American Journal of Clinical Oncology, University, Public health, Cancer, Associate, S-1 Executive Committee, Institute, Department, Cross-Cutting Programs Committee, Editing, A Call for Unity, Childhood cancer, All India Institute of Medical Sciences, New Delhi, Instagram, Research, Multimedia, American Society of Clinical Oncology, Executive Committee, YouTube, Birmingham, Board, Foundation, Twitter, Children's Oncology Group, Concurrent estate, Birmingham School, University of Birmingham Medical School, LinkedIn, Board of directors, ASCO, Journal, Genomics, Tobacco Products Scientific Advisory Committee, Haematopoietic system, Child, Dietary supplement, Management

Dr. Bhatia has long supported the St. Baldrick's Foundation and its mission to conquer childhood cancers.

Key Points: 
  • Dr. Bhatia has long supported the St. Baldrick's Foundation and its mission to conquer childhood cancers.
  • "I was drawn to pediatric oncology to provide support to families who are going through the unimaginable," said Dr. Bhatia.
  • "Being a mother, myself has added even more perspective to my work and increased my ability to care for kids with cancer.
  • She is also a member of the NCI National Cancer Policy Forum and the NCI Clinical Trials Advisory Committee.

Hyundai Hope On Wheels Announces 2021 Grant Award Winners

Retrieved on: 
목요일, 9월 16, 2021
Hyundai Motor America, National Childhood Cancer Awareness Month, Child, Children's Oncology Group, Hyundai, Oncology, Hope, Hospital, Research, Cancer, Awareness, Dietary supplement, Heavy equipment

Since then, Hyundai and its dealers have awarded more than $185 million to help end childhood cancer through Hyundai Hope On Wheels.

Key Points: 
  • Since then, Hyundai and its dealers have awarded more than $185 million to help end childhood cancer through Hyundai Hope On Wheels.
  • To honor that legacy and in recognition of National Childhood Cancer Awareness Month, Hyundai Hope On Wheels launched its "We win with hope."
  • Primary funding for Hyundai Hope On Wheels comes from Hyundai Motor America and its more than 820 U.S. dealers.
  • Since its inception, Hyundai Hope On Wheels has awarded $185 million in support of more than 1,000 childhood cancer research grants.

International Myeloma Foundation Congratulates Board Member Dr. S. Vincent Rajkumar on Receiving the Prestigious Waldenström Award for Outstanding Research

Retrieved on: 
목요일, 9월 9, 2021

LOS ANGELES, Sept. 9, 2021 /PRNewswire/ -- International Myeloma Foundation Board Member Dr. S. Vincent Rajkumar, professor of medicine at the Mayo Clinic, was recognized Wednesday for his outstanding contribution to myeloma research by the International Myeloma Society .

Key Points: 
  • LOS ANGELES, Sept. 9, 2021 /PRNewswire/ -- International Myeloma Foundation Board Member Dr. S. Vincent Rajkumar, professor of medicine at the Mayo Clinic, was recognized Wednesday for his outstanding contribution to myeloma research by the International Myeloma Society .
  • Dr. Rajkumar received the 2021 Waldenstrm Award, named for Prof. Jan Waldenstrm, a pioneer in treating blood cancers, during the society's annual meeting this week in Vienna.
  • Dr. Durie praised the collaborative efforts that Dr. Rajkumar has led over the years with members of the International Myeloma Working Group , the research arm of the International Myeloma Foundation.
  • Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest foundation focusing specifically on multiple myeloma.